The Trump administration’s plan to cut federal research funding threatens 565 ongoing experiments involving cannabis, according to an MJBizDaily review and interviews with scientists and academics.

An accompanying freeze of new National Institutes of Health (NIH) grants is also stymieing future research at a key moment – and raising questions about the fate of marijuana rescheduling as well as suggesting profound consequences for the regulated MJ industry.

ADVERTISEMENT

The NIH announced Feb. 7 that it would drastically reduce to no more than 15% the amount of “indirect costs” – money used to cover administrative and facility-related bills – financed by federal research grants.

Without fully funded indirect costs, “I literally cannot do my research,” Angela Bryan, a professor of psychology and neuroscience at the

Read full article on Marijuana Business Daily

(This is the first installment in a series – a collaboration with the Marijuana Policy Project – highlighting demographic shifts within medical cannabis registries nationwide.)

The expansion of adult-use marijuana sales to 21 states has ushered in a new era of commercialism in the U.S. cannabis industry.

For some retailers, that means a concentration of certain well-performing products.

ADVERTISEMENT

For some medical marijuana patients, that means less access to full-spectrum cannabis stock-keeping units (SKUs).

Inventory rightsizing is a key element for retail success, particularly given the dramatic shifts in customer and product demand after a market’s conversion to recreational sales.

“In most adult-use legalization states, the number of registered patients has dropped significantly since legalization passed,” Karen O’Keefe, director of state policies for the

Read full article on Marijuana Business Daily

Missouri marijuana processor Delta Extraction has lost its final appeal, resulting in the termination of its business license after its role in a massive 2023 product recall.

According to the Missouri Independent, the state’s Administrative Hearing Commission this week upheld an earlier decision by state regulators who suspended Delta Extraction’s marijuana business license in August 2023, accusing the company of sourcing materials from an unlicensed facility.

ADVERTISEMENT

The commission essentially agreed with the Division of Cannabis Regulation (DCR) that Delta Extraction violated Missouri law by infusing products with THCA sourced from outside the state.

In a 137-page ruling issued Tuesday, the Administrative Hearing Commission said the company had a “corporate culture of lax compliance with regulatory requirements,” the Independent reported.

An attorney representing

Read full article on Marijuana Business Daily